Empaa-M 12.5/500mg Tablet

Empaa-M 12.5/500mg Tablet is a combination medication containing two active ingredients: empagliflozin & metformin Empagliflozin belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors, while metformin is a biguanide antidiabetic agent. This combination tablet is used for the management of type 2 diabetes mellitus. Empagliflozin works by inhibiting SGLT2 in the kidneys, reducing glucose reabsorption and increasing urinary glucose excretion. Metformin decreases glucose production in the liver and improves insulin sensitivity in peripheral tissues.

Uses:

Empaa-M 12.5/500mg Tablet is indicated for:

1. Type 2 Diabetes Mellitus: It helps improve glycemic control in adults with type 2 diabetes mellitus by lowering blood sugar levels through complementary mechanisms of action.
2. Cardiovascular Risk Reduction: In addition to glycemic control, empagliflozin has been shown to reduce the risk of cardiovascular events, such as heart attacks, strokes, and cardiovascular death, in patients with established cardiovascular disease.

Side Effects:

While generally well-tolerated, Empaa-M 12.5/500mg Tablet may cause some side effects, including:

1. Genital yeast infections (in both women and men)
2. Urinary tract infections
3. Increased urination
4. Dehydration
5. Hypotension (low blood pressure)
6. Gastrointestinal disturbances (such as diarrhea, nausea, and abdominal discomfort)
7. Hypoglycemia (low blood sugar), particularly when used in combination with insulin or sulfonylureas

Precautions:

Before using Empaa-M 12.5/500mg Tablet:

• Inform your healthcare provider about any pre-existing medical conditions, allergies, or medications you are currently taking.
• Use caution in patients with impaired renal function, as both empagliflozin and metformin may affect kidney function.
• Monitor blood sugar levels regularly, especially when initiating or adjusting therapy with Empaa-M 12.5/500mg Tablet.
• Pregnant or breastfeeding individuals should consult their healthcare provider before using this medication.

When Not to Use:

Empaa-M 12.5/500mg Tablet should not be used in individuals with:

• Type 1 diabetes mellitus
• Diabetic ketoacidosis
• Severe renal impairment or end-stage renal disease requiring dialysis
• Hypersensitivity to empagliflozin, metformin, or any components of the tablet

Tags: .

FAQ:

1. How should Empaa-M 12.5/500mg Tablet be taken? Take Empaa-M 12.5/500mg Tablet orally, usually once daily with the evening meal, to minimize the risk of gastrointestinal side effects. Swallow the tablet whole, without chewing or crushing.
2. Can Empaa-M 12.5/500mg Tablet be used alone or in combination with other diabetes medications? Empaa-M 12.5/500mg Tablet is a combination medication and is typically used as an initial or add-on therapy for type 2 diabetes mellitus. It may be used alone or in combination with other antidiabetic agents, as prescribed by a healthcare provider.
3. Is weight loss a common side effect of Empaa-M 12.5/500mg Tablet? Yes, some individuals may experience weight loss while taking empagliflozin due to its mechanism of action, which promotes the excretion of glucose and calories in the urine.
4. Are there any special dietary restrictions when taking Empaa-M 12.5/500mg Tablet? No specific dietary restrictions are associated with Empaa-M 12.5/500mg Tablet. However, maintaining a healthy diet and regular exercise are essential components of diabetes management.
5. How long does it take for Empaa-M 12.5/500mg Tablet to start working? Empaa-M 12.5/500mg Tablet typically begins to lower blood sugar levels within a few days to weeks of initiating therapy. However, it may take several weeks to months to achieve maximum glycemic control. Individual response may vary.